Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of medicinal composition containing amlodipine in preparing medicine for treating lower urinary tract disease

A kind of technology of amlodipine and composition, which is applied in the directions of drug combination, medical preparations containing active ingredients, urinary system diseases, etc., and can solve the problems such as the inability to reduce the size of the prostate gland.

Inactive Publication Date: 2008-04-30
SHENZHEN AUSA PHARM CO LTD
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] 2. α-receptor blockers: such as terazosin, tamsulosin, etc., relax the urethra by inhibiting the muscle contraction of the posterior urethra of the bladder neck, improve the urinary flow rate, but cannot reduce the volume of the prostate
Although the relationship between hypertension and BPH / LUTS is not yet clear, a large number of literatures have shown that hypertension and BPH / LUTS are related, and the two may affect each other

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of medicinal composition containing amlodipine in preparing medicine for treating lower urinary tract disease
  • Application of medicinal composition containing amlodipine in preparing medicine for treating lower urinary tract disease
  • Application of medicinal composition containing amlodipine in preparing medicine for treating lower urinary tract disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Effect of amlodipine on BPH rats.

[0051] Animals and Groups

[0052] SPF grade male SD rats were randomly divided into 5 groups, namely blank group (sham operation group) 30 rats, model group 30 rats, amlodipine 1 group (A1, 0.25mg / kg) 15 rats, amlodipine 2 group (A2, 0.5mg / kg) 20, terazosin group (T, 0.2mg / kg) 20; get SHR rats (hereditary hypertension and benign prostatic hyperplasia rats) 20 as amlodipine 3 groups (A3, 0.5 mg / kg), of which the terazosin group was used as the positive control group.

[0053] Model establishment and administration

[0054]After SD model rats were anesthetized by intraperitoneal injection of 3.5% chloral hydrate 350mg / kg, bilateral testes were removed under aseptic conditions, penicillin 20,000 u / kg was injected intramuscularly for 3 consecutive days, and subcutaneous injection dissolved in olive oil was started 1 week later. Testosterone propionate 0.5mg / one, once a day, for 21 consecutive days.

[0055] After subcutaneo...

Embodiment 2

[0086] Example 2 The effect of amlodipine on improving lower urinary tract symptoms and lowering blood pressure in patients with lower urinary tract symptoms complicated with mild to moderate essential hypertension.

[0087] Statistical inclusion criteria: 1) Male patients aged 50-75 years; 2) Systolic blood pressure 140-180mm Hg and / or diastolic blood pressure 90-120mm Hg, for the blood pressure of the research subjects who have participated in the hypertension project of this research center in the past: Systolic blood pressure 135-180mm Hg and / or diastolic blood pressure 85-120mm Hg; 3) IPSS score ≥ 8 points.

[0088] Exclusion criteria: 1) history of allergy to amlodipine or terazosin; 2) known or suspected secondary hypertension; 3) prostate cancer; 4) serious medical diseases; 5) severe or active Patients with heart / cerebral insufficiency; 6) Severe tobacco and alcohol addiction and drug addiction; 7) Obvious abnormalities in laboratory tests or signs, and according to t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the usage of a medicament composition with amlodipine in preparing medicament for curing lower urinary tract diseases. The diseases refer to benign prostatic phyperplasia, syndrome of lower urinary tract, or hypermobility syndrome of bladder, in particular relates to lower urinary tract diseases accompany with high blood pressure, wherein the amlodipine is one of amlodipine, active metabolite of amlodipine, L-amlodipine, medicinal precursor of amlodipine, medicinal salt of amlodipine, medicinal salt of active metabolite of amlodipine and medicinal salt of medicinal precursor of amlodipine. The medical content of the amlodipine is 1mg-10mg. The invention relates to the field of medicament.

Description

technical field [0001] The invention belongs to the field of medicine. The present invention relates to the use of a pharmaceutical composition containing amlodipine in the preparation of medicines for treating lower urinary tract diseases. syndrome or use in medicines for overactive bladder. Background technique [0002] Benign prostatic hyperplasia (benign prostate hyperplasia, BPH) is the most common chronic disease among middle-aged and elderly men, and its incidence increases with the aging of the social population. Epidemiological survey of adult benign prostatic hyperplasia in Shanghai shows that the prevalence of benign prostatic hyperplasia in men aged 60 is 50% [Shi Rong, Wang Yixin, Jing Jing. Epidemiological survey of benign prostatic hyperplasia in Shanghai adults. Journal of Shanghai Second Medical University, 1999, 19(3): 27-22.]. A survey of 3,361 elderly people over 60 years old in six cities found that the total incidence of BPH was 43.68%, and the incid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4422A61P13/08A61P13/02
CPCA61K31/4422A61P13/02A61P13/08A61P13/10A61P9/12
Inventor 徐希平李劲彤邢厚恂秦献辉刘海鹏陈明侠于多戴成祥徐艳龙王燕陈光亮
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com